197 related articles for article (PubMed ID: 27997431)
1. Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.
Micevic G; Theodosakis N; Taube JM; Bosenberg MW; Rodić N
Melanoma Res; 2017 Apr; 27(2):85-96. PubMed ID: 27997431
[TBL] [Abstract][Full Text] [Related]
2. 5-Hydroxymethylcytosine Expression in Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma.
Pavlova O; Fraitag S; Hohl D
J Invest Dermatol; 2016 Dec; 136(12):2453-2461. PubMed ID: 27456754
[TBL] [Abstract][Full Text] [Related]
3. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma.
Lian CG; Xu Y; Ceol C; Wu F; Larson A; Dresser K; Xu W; Tan L; Hu Y; Zhan Q; Lee CW; Hu D; Lian BQ; Kleffel S; Yang Y; Neiswender J; Khorasani AJ; Fang R; Lezcano C; Duncan LM; Scolyer RA; Thompson JF; Kakavand H; Houvras Y; Zon LI; Mihm MC; Kaiser UB; Schatton T; Woda BA; Murphy GF; Shi YG
Cell; 2012 Sep; 150(6):1135-46. PubMed ID: 22980977
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.
Chatterjee A; Stockwell PA; Ahn A; Rodger EJ; Leichter AL; Eccles MR
Oncotarget; 2017 Jan; 8(4):6085-6101. PubMed ID: 28030832
[TBL] [Abstract][Full Text] [Related]
5. Loss of the epigenetic mark, 5-Hydroxymethylcytosine, correlates with small cell/nevoid subpopulations and assists in microstaging of human melanoma.
Lee JJ; Cook M; Mihm MC; Xu S; Zhan Q; Wang TJ; Murphy GF; Lian CG
Oncotarget; 2015 Nov; 6(35):37995-8004. PubMed ID: 26462027
[TBL] [Abstract][Full Text] [Related]
6. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
7. 5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms.
Lee JJ; Vilain RE; Granter SR; Hu NR; Bresler SC; Xu S; Frank AH; Mihm MC; Saw RP; Fletcher CD; Scolyer RA; Murphy GF; Lian CG
J Cutan Pathol; 2017 Mar; 44(3):249-255. PubMed ID: 28032662
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of dual 5-hydroxymethylcytosine/Melan-A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: An effective first-line test for the workup of sentinel lymph node specimen.
Siref AB; Huynh CAT; Balzer BL; Frishberg DP; Essner R; Shon W
J Cutan Pathol; 2019 Apr; 46(4):261-266. PubMed ID: 30632191
[TBL] [Abstract][Full Text] [Related]
9. Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas.
Bastian BC; Xiong J; Frieden IJ; Williams ML; Chou P; Busam K; Pinkel D; LeBoit PE
Am J Pathol; 2002 Oct; 161(4):1163-9. PubMed ID: 12368190
[TBL] [Abstract][Full Text] [Related]
10. Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors.
Larson AR; Dresser KA; Zhan Q; Lezcano C; Woda BA; Yosufi B; Thompson JF; Scolyer RA; Mihm MC; Shi YG; Murphy GF; Lian CG
Mod Pathol; 2014 Jul; 27(7):936-44. PubMed ID: 24390216
[TBL] [Abstract][Full Text] [Related]
11. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
12. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi.
Healy E; Belgaid CE; Takata M; Vahlquist A; Rehman I; Rigby H; Rees JL
Cancer Res; 1996 Feb; 56(3):589-93. PubMed ID: 8564976
[TBL] [Abstract][Full Text] [Related]
13. The role of 5-hydroxymethylcytosine in melanoma.
Li FJ; Li LM; Zhang RH; Xu C; Zhou P; Long J; Hu G; Jiang MJ
Melanoma Res; 2017 Jun; 27(3):175-179. PubMed ID: 28225433
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
[TBL] [Abstract][Full Text] [Related]
15. Melanocytic Nevi and the Genetic and Epigenetic Control of Oncogene-Induced Senescence.
Huang JM; Chikeka I; Hornyak TJ
Dermatol Clin; 2017 Jan; 35(1):85-93. PubMed ID: 27890240
[TBL] [Abstract][Full Text] [Related]
16. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
17. Distinct global DNA methylation status in B-cell lymphomas: immunohistochemical study of 5-methylcytosine and 5-hydroxymethylcytosine.
Matsuda I; Imai Y; Hirota S
J Clin Exp Hematop; 2014; 54(1):67-73. PubMed ID: 24942948
[TBL] [Abstract][Full Text] [Related]
18. Classifying melanocytic tumors based on DNA copy number changes.
Bastian BC; Olshen AB; LeBoit PE; Pinkel D
Am J Pathol; 2003 Nov; 163(5):1765-70. PubMed ID: 14578177
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide characterization of 5-hydoxymethylcytosine in melanoma reveals major differences with nevus.
Salgado C; Oosting J; Janssen B; Kumar R; Gruis N; van Doorn R
Genes Chromosomes Cancer; 2020 Jun; 59(6):366-374. PubMed ID: 32017278
[TBL] [Abstract][Full Text] [Related]
20. DNA binding of the p21 repressor ZBTB2 is inhibited by cytosine hydroxymethylation.
Lafaye C; Barbier E; Miscioscia A; Saint-Pierre C; Kraut A; Couté Y; Plo I; Gasparutto D; Ravanat JL; Breton J
Biochem Biophys Res Commun; 2014 Mar; 446(1):341-6. PubMed ID: 24607898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
